Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Euro-Med Laboratories PhilippinesPHS:EURO 83 5-Year Yield-on-Cost % is 16.19 as of Jul. 25, 2026, which is 142% above its 10-year median of 6.70. GuruFocus rates PHS:EURO with a GF Score™ of 83/100 and a GF Value™ of ₱1.03 (Fairly Valued). The stock has 7 warning signs investors should review. Among 513 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 94.15% on this metric.
The historical rank and industry rank for Euro-Med Laboratories Philippines's 5-Year Yield-on-Cost % or its related term are showing as below:
PHS:EURO'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.5 Med: 6.7 Max: 19.46
Current: 16.19
During the past 13 years, Euro-Med Laboratories Philippines's highest Yield on Cost was 19.46. The lowest was 2.50. And the median was 6.70.
PHS:EURO's 5-Year Yield-on-Cost % is ranked better than 94.15% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs PHS:EURO: 16.19
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Euro-Med Laboratories Philippines 5-Year Yield-on-Cost % Related Terms
PHS:EURO vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Euro-Med Laboratories Philippines (PHS:EURO) has a 5-Year Yield-on-Cost % of 16.19 as of Jul. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Euro-Med Laboratories Philippines and its competitors. This is 142% above median its historical median of 6.70. Over the past decade, Euro-Med Laboratories Philippines' 5-Year Yield-on-Cost % has ranged from 2.50 to 19.46. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #30 out of 513 companies in the Drug Manufacturers industry, placing it in the top 5.8%.
Is Euro-Med Laboratories Philippines' 5-Year Yield-on-Cost % too high?
Euro-Med Laboratories Philippines' current 5-Year Yield-on-Cost % of 16.19 is 142% above median its 10-year median of 6.70. Over the past 10 years, this metric has ranged from a low of 2.50 to a high of 19.46. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.36. Euro-Med Laboratories Philippines' value of 16.19 is 586% above this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #30 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #30 out of 513 companies for 5-Year Yield-on-Cost %. This places Euro-Med Laboratories Philippines in the top 6% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.36. Euro-Med Laboratories Philippines' value of 16.19 is 586% above this benchmark. Historically, Euro-Med Laboratories Philippines' own 5-Year Yield-on-Cost % has ranged from 2.50 to 19.46 over the past decade. While the company's 10-year median is 6.70 vs. the industry median of 2.36, Euro-Med Laboratories Philippines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current 5-Year Yield-on-Cost % of 16.19 is 586% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current 5-Year Yield-on-Cost % is 16.19, which is 142% above median its own 10-year median of 6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.03, compared to a current price of ₱1.08 — trading 4.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 16.19, which is 142% above median its 10-year median of 6.70 and 586% above the Drug Manufacturers industry median of 2.36. Euro-Med Laboratories Philippines' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current 5-Year Yield-on-Cost % is 16.19 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.08 is trading 4.9% above its estimated GF Value™ of ₱1.03.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
5-Year Yield-on-Cost %: 16.19 (142% above median its 10-year median of 6.70)
GF Value™: ₱1.03 vs. price of ₱1.08 (4.9% above fair value)
Industry Position: 586% above the Drug Manufacturers median (#30 of 513)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
83GF Score
Get the complete analysis for PHS:EURO
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
